2 research outputs found
Synthesis and Evaluation of <i>N</i>‑Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV)
Small
molecule induced hepatitis B virus (HBV) capsid assembly
modulation is considered an attractive approach for new antiviral
therapies against HBV. Here we describe efforts toward the discovery
of a HBV capsid assembly modulator in a hit-to-lead optimization,
resulting in JNJ-632, a tool compound used to further profile the
mode of action. Administration of JNJ-632 (<b>54</b>) in HBV
genotype D infected chimeric mice resulted in a 2.77 log reduction
of the HBV DNA viral load
Nucleotide Prodrugs of 2′-Deoxy-2′-spirooxetane Ribonucleosides as Novel Inhibitors of the HCV NS5B Polymerase
The limited efficacy, in particular
against the genotype 1 virus,
as well as the variety of side effects associated with the current
therapy for hepatitis C virus (HCV) infection necessitates more efficacious
drugs. We found that phosphoramidate prodrugs of 2′-deoxy-2′-spirooxetane
ribonucleosides form a novel class of HCV NS5B RNA-dependent RNA polymerase
inhibitors, displaying EC<sub>50</sub> values ranging from 0.2 to
>98 μM, measured in the Huh7-replicon cell line, with no
apparent
cytotoxicity (CC<sub>50</sub> > 98.4 μM). Confirming recent
findings, the 2′-spirooxetane moiety was identified as a novel
structural motif in the field of anti-HCV nucleosides. A convenient
synthesis was developed that enabled the synthesis of a broad set
of nucleotide prodrugs with varying substitution patterns. Extensive
formation of the triphosphate metabolite was observed in both rat
and human hepatocyte cultures. In addition, after oral dosing of several
phosphoramidate derivatives of compound <b>21</b> to rats, substantial
hepatic levels of the active triphosphate metabolite were found